{"certainAgreement":{"otherDetails":"Our agreements with investigators vary; constant is our right to review results communications prior to public release, and embargo communications for a period of ≤60 days from submittal for review. We do not prohibit investigators from publishing, but we may require previously undisclosed confidential information, other than study results, to be removed from publications, and single-center publications are postponed until after publication of the trial's primary multicenter publication.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"email":"druginfo@exelixis.com","organization":"Exelixis, Inc.","phone":"855-292-3935","title":"Exelixis Medical Information"}}